Most patients with epilepsy become seizure-free during treatment with antiseizure medications (ASM) and current guidelines by the American Academy of Neurology (AAN) support ASM discontinuation in some individuals to reduce the side effect burden and improve quality of life (Gloss et al. Neurology 2021;97:1072-1081). Read More
Latest News
Utility of biomarkers in progressive MS
August 1, 2024The German Emerging Blood Biomarkers in Progressive Multiple Sclerosis (EmBioProMS) study examined neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) levels in patients with primary or secondary progressive MS (Abdelhak et al. Ann Clin Transl Neurol 2024;11:477-485). Mean age was 55 years; one-third of patients had no DMT exposure at the time of enrollment. Read More
Protein biomarker panel useful for MS diagnosis, prognosis
July 23, 2024A U.K. group has investigated 31 biomarkers for their potential utility in the diagnosis and prognosis of multiple sclerosis (Kodosaki et al. J Neuroinflamm 2024;21:52). The biomarkers examined included neurofilament-light chain (NfL), glial fibrillary acidic protein (GFAP), chitinase-3-like-1 protein (CHi3L1), pro-and anti-inflammatory cytokines (e.g. IL-6, IL-10), chemokines (e.g. CXCL12), complement proteins (e.g. C3, C5) and proteins in other pathways relevant to MS (e.g. vitamin D binding protein). CSF and serum samples were obtained from 77 people being investigated for a demyelinating condition and 80 controls. Read More
REPORT FROM EAN 2024 – THURSDAY, JULY 4, 2024
July 4, 202410th Congress of the European Academy of Neurology, Helsinki, Finland, June 29-July 2, 2024
The following summarizes some of the data presented at EAN 2024.